Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 [Yahoo! Finance]
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment [Yahoo! Finance]
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates